Pan-Coronavirus Protease Engagement and Differentiated Pharmacology of Antiviral Candidate CMX990
N. G. R. Dayan Elshan, Karen C. Wolff, Laura Riva, Malina A. Bakowski, Simeon Babarinde, Anshul Chaudhary, Mark Zeller, Ashley K. Woods, Gennadii A. Grabovyi, Katy B. Wilson, Rebecca A. Leonard, Briana Lynn McGovern, Jared Benjamin, Isidora D. Suazo, Mary Gordon, , Arnab K. Chatterjee
This study evaluates CMX990, a coronavirus Mpro inhibitor, showing broad antiviral activity against multiple coronaviruses and superior pharmacologic properties compared to existing inhibitors.
bioRxiv · Oct 1, 2026 · PreprintPharmacology & Toxicology